South African pharmaceutical company Aspen plans to seek regulatory approval for Eli Lilly’s diabetes drug Mounjaro (tirzepatide) across sub-Saharan Africa in 2026, marking a strategic push into a high-growth region. The move could unlock significant revenue potential as type 2 diabetes prevalence rises across the continent.
- Aspen (ASPN) intends to pursue Mounjaro approval in sub-Saharan Africa by 2026
- Mounjaro targets type 2 diabetes and obesity, with strong clinical performance data
- Sub-Saharan Africa has an estimated 45 million adults with diabetes, rising rapidly
- Projected annual sales of up to $150 million from Mounjaro across 10 core African markets within five years
- Expansion aligns with Aspen’s strategy to leverage global innovations in emerging markets
- Sector-wide implications for healthcare access and investor sentiment in pharmaceuticals
Aspen, trading under the ticker ASPN, has announced its intention to file for regulatory approval of Mounjaro in multiple sub-Saharan African markets before the end of 2026. The drug, developed by Eli Lilly and marketed as Mounjaro, is a dual GIP and GLP-1 receptor agonist that has demonstrated significant efficacy in managing type 2 diabetes and promoting weight loss. The decision underscores Aspen’s growing focus on expanding access to innovative chronic disease therapies in emerging markets. Sub-Saharan Africa is projected to see a 50% increase in diabetes cases by 2030, driven by urbanization, changing diets, and rising obesity rates. With an estimated 45 million adults currently living with diabetes in the region, Aspen’s entry could position the company as a key provider of advanced treatment options. While specific revenue projections for the region were not disclosed, analysts note that a successful launch of Mounjaro across 10 core markets—such as South Africa, Nigeria, Kenya, and Ghana—could generate up to $150 million in annual sales within five years. This expansion supports Aspen’s broader commercial strategy, which includes licensing agreements with global innovators and strengthening its presence in high-need markets. The initiative also impacts broader healthcare dynamics, potentially improving treatment access for millions while reinforcing investor confidence in Aspen’s international growth trajectory. The move comes amid steady performance in the healthcare sector, with the XLV ETF tracking a basket of major pharmaceutical firms, including Johnson & Johnson (JNJ), which remains a key competitor in diabetes therapeutics.